Business Wire

Hellas Direct Partners With Akur8 to Enhance Their Best-in-Class Pricing Process

26.4.2022 10:00:00 EEST | Business Wire | Press release

Share

Hellas Direct and Akur8 are delighted to announce their collaboration to strengthen Hellas Direct’s top-notch pricing process for motor and home insurance! Hellas Direct is a fast growing, digital-first, full-stack insurtech leveraging cutting-edge technology and AI. With this new alliance, Akur8 enters the Greek insurance market, extending its already strong presence in Europe, and reinforces its footprint among tech-fuelled disruptive insurtechs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426005010/en/

Specifically developed for insurers, Akur8’s solution enhances pricing processes by automating rate making, using Transparent Artificial Intelligence proprietary technology. Core benefits for insurers include increased predictive performance of pricing models and accelerated speed-to-accuracy, unlocking higher market reactivity and immediate business impact, while maintaining full transparency and control on the models created.

Hellas Direct is a digital-first, full-stack insurance company, empowered by cutting-edge technology and the use of advanced analytics. Modeling itself on Amazon, Hellas Direct aims to disrupt the insurance value chain by adopting an extreme focus on operational excellence and data analytics. The company is backed by a roster of leading investors, including the EBRD, Portage Ventures, IFC (a member of the World Bank), EiB, Endeavor Catalyst, and a number of world-renowned angel investors. By choosing Akur8 to empower its pricing team, Hellas Direct is ensuring smoothness of its pricing process end-to-end, from fast and transparent modeling to efficient and insightful rate building, with native ability to share and visualise the information across all stakeholders.

"We are delighted to support Hellas Direct in their fast and disruptive journey! Both Akur8 and Hellas Direct challenge the status quo and would not settle for less than excellence. We look forward to working with Hellas Direct’s expert pricing team to continue to bring leading-edge innovation and technology into the insurance world," said Samuel Falmagne, CEO of Akur8.

"Hellas Direct is growing impressively in Greece and in other European markets. This new collaboration allows Akur8 to expand its footprint in Europe, to reinforce its relevance among leading insurtechs, and to anchor its position as the best-in-class, revolutionary insurance pricing solution," comments Brune de Linares, Chief Customer Officer at Akur8.

"We took great care in building solid partnerships to fuel our ambitious growth. This alliance with Akur8 is no exception. By combining impressive modeling speed with highly qualitative customer support, Akur8 will allow us to keep our best-in-class pricing standards. We are particularly pleased with the scenario-testing capabilities of the Rate module and by the transparency that Akur8 brings, both at the modeling level and on the collaborative aspects across all stakeholders," concludes Giorgos Gakas, Head of Pricing at Hellas Direct.

About Akur8

Akur8 is revolutionizing insurance pricing with transparent AI. Akur8 developed a unique AI-based insurance pricing solution that automates modeling for insurance companies while keeping full transparency and control on the models created, as required by regulators worldwide. Akur8 is the only solution on the market reconciling Machine Learning and Actuarial worlds.

About Hellas Direct

Hellas Direct is an online insurance company which began operating in 2012 with one main goal: change the Greek insurance sector. Hellas Direct introduced its first innovations in the Greek car insurance sector and is now ready to bring change in other markets and sectors, going beyond insurance by offering mobility financing solutions. Hellas Direct was recently listed by the Financial Times as one of Europe’s 1,000 Fastest Growing Companies for the third time.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Akur8
Anne-Laure Klein
+330663794474
anne-laure.klein@akur8.com

For Hellas Direct
Giorgos Gakas
+306973263736
giorgos.gakas@hellasdirect.gr

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye